Novo Nordisk Launches Oral Wegovy in Germany to Challenge Eli Lilly

Key Facts

1Novo Nordisk has officially launched its oral Wegovy weight-loss treatment in Germany.

In a move reflecting the intensifying competition in the global weight-loss drug market, Novo Nordisk has launched the oral version of its popular drug Wegovy in the German market. According to reports, this launch aims to expand the company's market share in Europe and address growing competition from Eli Lilly in the obesity treatment sector. The introduction of the pill version provides a strategic alternative for patients who prefer oral medication over traditional injections.

This expansion places Novo Nordisk in direct competition with its primary rival, Eli Lilly, as both firms vie for dominance in the burgeoning metabolic health space. Per market data, LLY stock closed at $1157.83 (close August 31, 2026), having reached a day high of $1171.4479. The move into Germany is seen as a critical step in securing a foothold in a major European economy amid shifting sector dynamics.

Looking ahead, investors are monitoring how this launch will impact regional sales within the pharmaceutical sector. Regarding German economic context, consumer confidence data from August 27, 2026, showed a slight improvement to -26.6. Market participants will continue to watch LLY price levels, which saw a day low of $1147 on August 31, 2026, to gauge the competitive response to Novo Nordisk's latest market entry.